Polaryx Therapeutics (PLYX) Financials: Revenue & Earnings
PLYX$1.86-0.02 -1.06%
$92.71M
Market Cap
—
P/E
—
Forward P/E
—
Score
Polaryx Therapeutics (PLYX) Financials: Revenue & Earnings
PLYX price $1.86 -0.02 -1.06%
- Ticker
- PLYX
- Price
- $1.86
- Change
- -0.02 -1.06%
- Market cap ?
- $92.71M
- Beta ?
- -8.91
- Sector
- Healthcare
- Industry
- Biotechnology
Fair value
PLYX fair value $1.82. Price $1.86. Price is about fair value.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-12 | — | -0.06 | — | — |
| 2026-08-13 | -0.03 | -0.04 | — | — |
| 2026-05-15 | -0.05 | -0.02 | — | — |
| 2026-03-24 | -0.13 | -0.02 | — | — |
| 2026-01-27 | -0.03 | — | — | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| No data yet. | |||||
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 13, holders -1 vs prior quarter. Ownership 4.54%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 1.66M | -516 | -0.03% | 4.41M |
| GEODE CAPITAL MANAGEMENT, LLC | 171.00K | 325 | +0.19% | 455.08K |
| VANGUARD FIDUCIARY TRUST CO | 105.07K | 516 | +0.49% | 279.49K |
| HRT FINANCIAL LP | 82.09K | 82.09K | New | 218.00K |
| STATE STREET CORP | 58.10K | 0 | 0.00% | 154.56K |
| BLACKROCK, INC. | 41.01K | 0 | 0.00% | 109.09K |
| JANE STREET GROUP, LLC | 31.44K | 31.44K | New | 83.63K |
| NORTHERN TRUST CORP | 27.99K | 0 | 0.00% | 74.44K |
| ALLWORTH FINANCIAL LP | 7.73K | 7.73K | New | 20.55K |
| VANGUARD GLOBAL ADVISERS, LLC | 6.32K | 0 | 0.00% | 16.81K |
| TOWER RESEARCH CAPITAL LLC (TRC) | 3.00K | 1.22K | +68.56% | 7.99K |
| UBS GROUP AG | 1.28K | -12.20K | -90.48% | 3.41K |
| FORTITUDE FAMILY OFFICE, LLC | 189 | 189 | New | 503 |
| BANK OF AMERICA CORP /DE/ | 0 | -25.88K | -100.00% | 0 |
| MORGAN STANLEY | 0 | -5.54K | -100.00% | 0 |
| GOLDMAN SACHS GROUP INC | 0 | -13.48K | -100.00% | 0 |
| MILLENNIUM MANAGEMENT LLC | 0 | -127.53K | -100.00% | 0 |
| SQUAREPOINT OPS LLC | 0 | -12.41K | -100.00% | 0 |
Earnings and financials
Polaryx Therapeutics, Inc. Common Stock (PLYX) trades at $1.86, with a market cap of $92.71M and a trailing P/E of n/a. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Insights · Dividends · Forecast · Financials · Learn